Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Afipia carboxidovorans OM5

ABSTRACT: Oligotropha carboxidovorans OM5 Genome sequencing

PROVIDER: PRJNA41025 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	GCA_000218565.1_sequence_report.txt	Txt

Items per page:

1 - 1 of 1

Similar Datasets

Afipia carboxidovorans

Project description:Oligotropha carboxidovorans overview

| PRJNA36857 | ENA

Afipia carboxidovorans OM4

Project description:Oligotropha carboxidovorans OM4 genome sequencing

| PRJNA66839 | ENA

Afipia carboxidovorans strain:SH125

Project description:Draft genome sequence of Afipia carboxidovorans strain SH125

| PRJDB17139 | ENA

Afipia carboxidovorans OM5

Project description:Carbon monoxide-utilizing bacterium

| PRJNA28805 | ENA

RNA-seq of Oligotropha carboxidovorans strain OM5, a promising candidate for the aerobic utilization of synthesis gas, heterotrophically (acetate) and autotrophically (syngas) grown.

Project description:Oligotropha carboxidovorans strain OM5 is an aerobic carboxidotrophic bacterium and potentially a promising candidate for such processes. We here performed RNA-Seq analysis comparing cells of this organism grown heterotrophically with acetate or autotrophically with CO2, CO and H2 as carbon and energy source and found a variety of chromosomally and of native plasmid-encoded genes to be highly differentially expressed. For RNA extraction and RNA-Seq, respectively, six aliquots of the sample of each culture replicate were pooled to gain enough cell mass and RNA, accordingly, while four biological replicates were processed for the RNA-Seq analysis. Total RNA was isolated from four biological replicates using Zymo Quick-RNA Miniprep Plus kit with bead beating and DNase-treatment (Zymo Research, Freiburg, Germany). Initially RNA quality was checked by Trinean Xpose (Gentbrugge,Belgium) and Agilent RNA Nano 6000 kit on Agilent 2100 Bioanalyzer (Agilent Technologies, Böblingen, Germany). Samples contaminated with DNA were treated with DNase again, cleaned as described above and rechecked by Xpose and Agilent Bioanalyzer. Finally RNA was free of DNA with an RNA Integrity Number (RIN) > 9 and rRNA Ratio [23s / 16s] > 1.5. Ribo-Zero rRNA Removal Kit (Bacteria) from Illumina (San Diego, CA, USA) was used to remove the ribosomal RNA molecules from the isolated total RNA. Removal of rRNA was checked by Agilent RNA Pico 6000 kit on Agilent 2100 Bioanalyzer (Agilent Technologies, Böblingen, Germany). RNA was free of detectable rRNA. TruSeq Stranded mRNA Library Prep Kit from Illumina (San Diego, CA, USA) was used to prepare cDNA libraries. TruSeq stranded cDNAs were sequenced paired end on an Illumina HiSeq1500 system, rapid mode using 70 bp read length.

2020-02-21 | E-MTAB-8786 | biostudies-arrayexpress

RNA-seq of Oligotropha carboxidovorans strain OM5, a promising candidate for the aerobic utilization of synthesis gas, heterotrophically (acetate) and autotrophically (syngas) grown.

Project description:RNA-seq of Oligotropha carboxidovorans strain OM5, a promising candidate for the aerobic utilization of synthesis gas, heterotrophically (acetate) and autotrophically (syngas) grown.

| PRJEB36726 | ENA

Nitrosomonas oligotropha strain:Nm76

Project description:Nitrosomonas oligotropha Nm76 genome sequencing

| PRJNA323343 | ENA

Nitrosomonas oligotropha strain:Nm75

Project description:Nitrosomonas oligotropha Nm75 genome sequencing

| PRJNA323342 | ENA

Nitrosomonas oligotropha strain:Nm49

Project description:Nitrosomonas oligotropha Nm49 genome sequencing

| PRJNA444079 | ENA

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data